Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Urology|September 8, 1998
Current status of intermittent androgen suppression in the treatment of prostate cancerG Theyer, G Hamilton
Wiener Medizinische Wochenschrift (1946)|January 1, 1993
[Calcium antagonists as modulators of multi-drug resistant tumor cells]G Hamilton, G Theyer, G Baumgartner
Journal of Biological Regulators and Homeostatic Agents|April 1, 1988
Experiences with continuous intraarterial administration of recombinant interferon alpha-2C (rIFN-alpha 2) for treatment of patients with advanced transitional cell bladder cancerW Scheithauer, G Theyer, O Zechner, et al.
Clinical and Experimental Immunology|May 1, 1991
Synergistic effect of coumarin (1,2 benzopyrone) and endotoxin in the induction of human interleukin-1K Stuhlmeier, G Theyer, G Baumgartner, et al.
Anticancer Research|September 1, 1994
In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cellsF Gabor, K Wollmann, G Theyer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell linesS Hofbauer, G Hamilton, G Theyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2000
Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patientsG Theyer, E Ulsperger, G Baumgartner, et al.
Herzschrittmachertherapie & Elektrophysiologie|June 5, 2009
[Does thermotherapy of prostatic hypertrophy interfere with pacemaker function? - First results of a pilot-study]G Jakl, M Nürnberg, K Steinbach, et al.
The Journal of Urology|November 1, 1993
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell linesG Theyer, M Schirmböck, T Thalhammer, et al.
British Journal of Cancer|January 1, 1997
Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapyG Theyer, S Holub, A Dürer, et al.
Pageof 2